Smart sensors vs. finger pricks: which works better for diabetes?
NCT ID NCT07595289
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two glucose monitoring methods—continuous glucose monitors (CGM) and traditional finger-prick tests—in adults with type 2 diabetes who are taking the drug dapagliflozin. The 120 participants will be split into two groups and followed for 12 weeks to see which method leads to better blood sugar control. The trial also tests whether a digital platform can run most of the study remotely, reducing the need for hospital visits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin
What this could lead to
If successful, this could show that combining a common diabetes drug with continuous glucose monitoring helps more people reach their blood sugar targets than traditional finger-prick testing.
What could go wrong
This is a small, early-stage trial (120 people) testing feasibility as much as effectiveness. The results may not apply to all people with diabetes, and the technology platform may have reliability issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••